中国肺动脉高压诊断与治疗指南(2021版)

2021-01-05 中华医学会呼吸病学分会 肺栓塞与肺血管病学组 中华医学杂志. 2021,101(01)

肺动脉高压(pulmonary hypertension, PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右

中文标题:

中国肺动脉高压诊断与治疗指南(2021版)

发布日期:

2021-01-05

简要介绍:

肺动脉高压(pulmonary hypertension, PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右心衰竭甚至死亡。近年来PH领域诊断及治疗策略不断更新,国内外在不同领域发表了PH相关指南和专家共识。为更好指导我国医师的临床实践,中华医学会呼吸病学分会肺栓塞与肺血管病学组、中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会基于当前的循证医学证据,制订了《中国肺动脉高压诊断与治疗指南(2021版)》。本指南系统评价了国内外近年来发表的PH领域系列指南和相关循证医学研究证据,增加了基于国人循证医学研究的数据,旨在进一步规范我国PH的诊断与治疗。 
 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国肺动脉高压诊断与治疗指南(2021版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=d88e21c00216906a, title=中国肺动脉高压诊断与治疗指南(2021版) , enTitle=, guiderFrom=中华医学杂志. 2021,101(01), authorId=0, author=, summary=肺动脉高压(pulmonary hypertension, PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右, cover=https://img.medsci.cn/2021831/1630424829258_2020535.jpg, journalId=0, articlesId=null, associationId=1628, associationName=中华医学会呼吸病学分会 肺栓塞与肺血管病学组, associationIntro=, copyright=0, guiderPublishedTime=Tue Jan 05 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="row"><span id="ChDivSummary" class="abstract-text" style="color: #666666;">肺动脉高压(pulmonary hypertension, PH)是指由多种异源性疾病(病因)和不同发病机制所致肺血管结构或功能改变,引起肺血管阻力和肺动脉压力升高的临床和病理生理综合征,继而发展成右心衰竭甚至死亡。近年来PH领域诊断及治疗策略不断更新,国内外在不同领域发表了PH相关指南和专家共识。为更好指导我国医师的临床实践,中华医学会呼吸病学分会肺栓塞与肺血管病学组、中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会基于当前的循证医学证据,制订了《中国肺动脉高压诊断与治疗指南(2021版)》。本指南系统评价了国内外近年来发表的PH领域系列指南和相关循证医学研究证据,增加了基于国人循证医学研究的数据,旨在进一步规范我国PH的诊断与治疗。&nbsp;</span></div> <div class="row">&nbsp;</div>, tagList=[TagDto(tagId=1179, tagName=肺动脉高压)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1179, guiderKeyword=肺动脉高压, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6087, appHits=1436, showAppHits=0, pcHits=1670, showPcHits=4642, likes=8, shares=188, comments=57, approvalStatus=1, publishedTime=Tue Aug 31 23:53:41 CST 2021, publishedTimeString=2021-01-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Aug 31 23:47:15 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:19:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国肺动脉高压诊断与治疗指南(2021版).pdf)])
中国肺动脉高压诊断与治疗指南(2021版).pdf
下载请点击:
评论区 (48)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2105673, encodeId=2bcc21056e348, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:27 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105672, encodeId=ce7a21056e2c4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:20 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104012, encodeId=bb312104012cd, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e855264640, createdName=1480cf7bm57暂无昵称, createdTime=Fri Dec 02 21:19:27 CST 2022, time=2022-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103866, encodeId=9e102103866f8, content=打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Fri Dec 02 10:04:08 CST 2022, time=2022-12-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2103467, encodeId=e0a8210346ecb, content=白塞病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Wed Nov 30 09:59:54 CST 2022, time=2022-11-30, status=1, ipAttribution=四川省)]
    2022-12-12 1e1fad9am68(暂无匿称) 来自北京

    好好好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2105673, encodeId=2bcc21056e348, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:27 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105672, encodeId=ce7a21056e2c4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:20 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104012, encodeId=bb312104012cd, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e855264640, createdName=1480cf7bm57暂无昵称, createdTime=Fri Dec 02 21:19:27 CST 2022, time=2022-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103866, encodeId=9e102103866f8, content=打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Fri Dec 02 10:04:08 CST 2022, time=2022-12-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2103467, encodeId=e0a8210346ecb, content=白塞病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Wed Nov 30 09:59:54 CST 2022, time=2022-11-30, status=1, ipAttribution=四川省)]
    2022-12-12 1e1fad9am68(暂无匿称) 来自北京

    非常感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2105673, encodeId=2bcc21056e348, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:27 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105672, encodeId=ce7a21056e2c4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:20 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104012, encodeId=bb312104012cd, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e855264640, createdName=1480cf7bm57暂无昵称, createdTime=Fri Dec 02 21:19:27 CST 2022, time=2022-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103866, encodeId=9e102103866f8, content=打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Fri Dec 02 10:04:08 CST 2022, time=2022-12-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2103467, encodeId=e0a8210346ecb, content=白塞病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Wed Nov 30 09:59:54 CST 2022, time=2022-11-30, status=1, ipAttribution=四川省)]
    2022-12-02 1480cf7bm57暂无昵称 来自广东省

    好好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2105673, encodeId=2bcc21056e348, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:27 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105672, encodeId=ce7a21056e2c4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:20 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104012, encodeId=bb312104012cd, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e855264640, createdName=1480cf7bm57暂无昵称, createdTime=Fri Dec 02 21:19:27 CST 2022, time=2022-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103866, encodeId=9e102103866f8, content=打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Fri Dec 02 10:04:08 CST 2022, time=2022-12-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2103467, encodeId=e0a8210346ecb, content=白塞病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Wed Nov 30 09:59:54 CST 2022, time=2022-11-30, status=1, ipAttribution=四川省)]
    2022-12-02 ms3000002106324246 来自四川省

    打卡

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2105673, encodeId=2bcc21056e348, content=好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:27 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2105672, encodeId=ce7a21056e2c4, content=非常感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a482014716, createdName=1e1fad9am68(暂无匿称), createdTime=Mon Dec 12 10:36:20 CST 2022, time=2022-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2104012, encodeId=bb312104012cd, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e855264640, createdName=1480cf7bm57暂无昵称, createdTime=Fri Dec 02 21:19:27 CST 2022, time=2022-12-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2103866, encodeId=9e102103866f8, content=打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Fri Dec 02 10:04:08 CST 2022, time=2022-12-02, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2103467, encodeId=e0a8210346ecb, content=白塞病, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43718258358, createdName=ms3000002106324246, createdTime=Wed Nov 30 09:59:54 CST 2022, time=2022-11-30, status=1, ipAttribution=四川省)]
    2022-11-30 ms3000002106324246 来自四川省

    白塞病

    0

拓展阅读

先天性心脏病相关肺动脉高压中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2012-12-01

2013先天性心脏病相关性肺动脉高压诊治专家共识

中国心血管病相关专家小组(统称) · 2013-05-16

2014 肺动脉高压治疗流程

中国呼吸科专家组(统称) · 2014-01-02

2014 ACCP成人肺动脉高压药物治疗指南

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2014-06-17